Stimcell Energetics Inc.

Stimcell Energetics Inc. is a biotech company focused on the discovery, development, and commercialization of therapeutic and non-therapeutic products. These products are designed to enhance cellular function, promote general wellness, and alleviate health complications such as aging, insulin sensitivity, high blood pressure, neuropathy, and kidney function. The company was incorporated in Nevada on March 19, 2010. On April 26, 2016, it formed a wholly owned subsidiary, Cell MedX (Canada) Corp., in British Columbia. The company's primary focus is on the continued research and development of its eBalance® Technology and its eBalance® Home System. Stimcell Energetics Inc. acquired its proprietary microcurrent technology, known as eBalance® Technology, in 2014 through a Technology Purchase Agreement. This technology is designed for use in the treatment of diabetes and related ailments. eBalance® Technology is based on the science of bioelectric signals and their effect on epigenetic events within the human body, as well as their ability to modify and affect the behavior of cells, tissues, and organs. The eBalance® Technology utilizes microcurrent electrical therapy (MEY) to deliver subsensory micro amperage current to the patient or user to support general wellness or provide temporary relief of pain. Effective November 1, 2024, the company completed a 1-for-15 reverse stock split, decreasing its authorized capital from 7,500,000,000 shares to 500,000,000 shares of common stock with a par value of $0.001. Outstanding shares decreased from 297,236,373 to 19,816,272. Concurrent with the reverse split, the company changed its name from "Cell MedX Corp." to "Stimcell Energetics Inc."